TTI-622 Demonstrates Safety and Preliminary Activity in R/R Lymphomas
December 6th 2020In patients with relapsed or refractory lymphoma, treatment with the investigational CD47-blocker TTI-622 appeared well tolerated and demonstrated preliminary activity, according to results from a phase 1a clinical trial presented in a poster during the 2020 American Society of Hematology Virtual Annual Meeting.
Read More
Asciminib Represents New Safe and Effective Treatment Option for Heavily Pretreated CML
December 6th 2020A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.
Read More
UCART22 Safe and Active in CD22-Expressing B-Cell ALLs
December 6th 2020Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.
Read More
Novel BCMA-Targeted Immunotherapy Demonstrates Safety, Convenience in Relapsed/Refractory Myeloma
December 6th 2020A novel BCMA and CD3 targeted bispecific T-cell engaging immunotherapy agent TNB-383B has demonstrated significant responses at higher dose levels and tolerability at all dose levels, including mild cases of cytokine release syndrome, according to initial results of a phase 1 trial presented during the 2020 American Society of Hematology Annual Meeting.
Read More
Natural Killer Cell Proliferation Achieved in MDS/AML With Novel TriKE
December 6th 2020Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.
Read More
Belamaf With Bortezomib/Dexamethasone Shows High ORR, Acceptable Safety in R/R Multiple Myeloma
December 6th 2020The ongoing phase 1/2 DREAMM-6 trial demonstrated clinical activity and a good safety profile with the combination of belantamab mafodotin, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.
Read More
HRQoL Maintained With Oral Azacitidine Along With OS and RFS Improvement in AML
December 6th 2020Azacitidine administered orally to patients with acute myeloid leukemia demonstrated significant improvements in overall survival and relapse-free survival while sustaining the health-related quality of life compared with placebo.
Read More
Novel RARα Agonist Combo Induces Clinical Activity in Heavily Pretreated R/R AML
December 6th 2020The addition of the oral selective RARα agonist SY-1425 to azacitidine induced clinical activity as treatment of patients with heavily pretreated relapsed/refractory acute myeloid leukemia with RARA positivity.
Read More
Enriched CAR T-Cell bb21217 Improves Response and Duration in Patients With Multiple Myeloma
December 5th 2020Enriching the CAR molecule bb2121 with the PI3K inhibitor bb007 improved response and extended duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
Read More
Jelmyto Induces Durable Responses in Patients With Low-Grade Upper Tract UC
December 5th 2020Treatment with mitomycin-containing reverse thermal gel, led to complete responses in over 50% of patients with low-grade upper tract urothelial carcinoma, which were maintained at 1 year, final results from the pivotal phase 3 OLYMPUS trial show.
Read More
Ide-cel Data Continues to Demonstrate Promise in Triple-Class Refractory Myeloma
December 5th 2020Updated findings from the phase 1 CRB-401 trial of the chimeric antigen receptor T-cell therapy idecabtagene vicleucel showed a consistently favorable risk profile as well as durable, ongoing responses in heavily pretreated patients with multiple myeloma.
Read More
Venetoclax/Rituximab Shows 5-Year Survival Benefit in Relapsed/Refractory CLL
December 5th 2020Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.
Read More
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
Selinexor Demonstrates Significant Benefit in Pretreated Multiple Myeloma as Once Weekly Regimen
December 5th 2020Treatment with selinexor, bortezomib, and dexamethasone demonstrated an increase in overall response rate and progression-free survival in patients with multiple myeloma and high cytogenetic risk despite a dosing schedule that utilized 40% less bortezomib and 25% less dexamethasone during the first 24 weeks of treatment.
Read More
Clinical Activity and Durable Responses Observed With MEDI-570 in R/R T-cell Lymphomas
December 5th 2020In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.
Read More
Overall Survival in High-Risk Myelofibrosis Improved With High-Dose Imetelstat
December 5th 2020Higher doses of telomerase inhibitor imetelstat demonstrated better overall survival, spleen response, and symptom response in patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors in the phase 2 IMbark study.
Read More
Survival Outcome Influenced by Racial and Ethnic Related Socioeconomic Disparities in AML
December 5th 2020Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.
Read More
Prolonged Survival Seen With Azacitadine After Induction, Consolidation Therapy in AML
December 5th 2020Patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy had significantly prolonged overall survival and relapse-free survival with azacitidine.
Read More
Phase 3 Trial Shows More Efficacy With Ruxolitinib Than Best Available Therapy in Chronic GVHD
December 5th 2020The phase 3 REACH3 trial of ruxolitinib in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids demonstrated significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement compared with best available therapy.
Read More
Novel HIF-2α Inhibitor Achieved Durable Responses in VHL-Associated RCC
December 5th 2020Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.
Read More